Jump to content

ALMANAC

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Citation bot (talk | contribs) at 03:33, 30 July 2021 (Alter: url. URLs might have been anonymized. | Use this bot. Report bugs. | Suggested by Abductive | Category:Oncology stubs | #UCB_Category 55/220). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

ALMANAC is a major breast cancer trial. The acronym stands for "Axillary Lymphatic Mapping Against Nodal Axillary Clearance." This major randomized trial performed in several centres in the UK produced clear evidence that sentinel node biopsy (SNB), used to stage axillary spread of disease, can be used with low failed localization and false negative rates, provided both radioisotope and blue dye are used to locate the sentinel nodes.[1]

References[edit]

  1. ^ Hiram S Cody (2003). Sentinel Lymph Node Biopsy. Informa Health Care. p. 237. ISBN 1-84184-034-3.